CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients.

M, Green; MG, Michaels; BZ, Katz; M, Burroughs; D, Gerber; BL, Shneider; K, Newell; D, Rowe; J, Reyes

doi:10.1111/j.1600-6143.2006.01394.x

Public

CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients.

Shared by NobleBlocks on Aug 1, 2006 • 12:00 AM UTC

Authors:

Green M

Michaels MG

Katz BZ

Abstract

A randomized controlled trial of CMV-IVIG (cytomegalovirus-intravenous immunoglobulin) for prevention of Epstein Barr virus (EBV) posttransplant lymphoproliferative disease (PTLD) in pediatric liver transplantation (PLTx) recipients was begun in Pittsburgh and subsequently expanded to four additiona...

Discussions